Regeneron Pharmaceuticals
(REGN)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2020 | 06-2020 | 03-2020 | 12-2019 | 09-2019 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 1,573,000 | 1,992,200 | 2,208,200 | 1,617,800 | 1,384,800 |
| Marketable Securities | 1,452,900 | 1,152,000 | 1,795,200 | 1,596,500 | 1,493,100 |
| Receivables | 4,039,500 | 2,811,300 | 2,933,200 | 2,785,600 | 2,660,000 |
| Inventories | 1,801,600 | 1,640,900 | 1,480,900 | 1,415,500 | 1,344,300 |
| TOTAL | $9,097,600 | $7,860,200 | $8,644,100 | $7,689,100 | $7,109,100 |
| Non-Current Assets | |||||
| PPE Net | 3,138,300 | 3,031,400 | 2,944,600 | 2,890,400 | 2,771,400 |
| Investments And Advances | 2,875,100 | 2,587,600 | 3,236,400 | 3,256,800 | 3,112,600 |
| Other Non-Current Assets | 973,000 | 949,500 | 932,400 | 968,901 | 946,200 |
| TOTAL | $6,986,400 | $6,568,500 | $7,113,400 | $7,116,101 | $6,830,200 |
| Total Assets | $16,084,000 | $14,428,700 | $15,757,500 | $14,805,200 | $13,939,300 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | N/A | 1,500,000 | N/A | N/A | N/A |
| Accounts payable and accrued liabilities | 443,100 | 380,100 | 347,800 | 418,100 | 335,600 |
| Other current liabilities | 1,399,900 | 1,360,800 | 1,228,200 | 1,296,400 | 821,100 |
| TOTAL | $2,337,800 | $3,702,400 | $2,055,200 | $2,096,600 | $1,765,400 |
| Non-Current Liabilities | |||||
| Long Term Debt | 1,978,300 | N/A | N/A | N/A | N/A |
| Deferred Revenues | 494,800 | 461,500 | 479,200 | 382,100 | 608,700 |
| Other Non-Current Liabilities | 821,000 | 848,200 | 772,000 | 799,700 | 273,000 |
| TOTAL | $3,620,700 | $1,668,900 | $1,569,300 | $1,618,900 | $1,669,500 |
| Total Liabilities | $5,958,500 | $5,371,300 | $3,624,500 | $3,715,500 | $3,434,900 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 106,706 | 106,392 | 112,522 | 110,020 | 109,796 |
| Common Shares | 100 | 100 | 100 | 100 | 100 |
| Retained earnings | 9,743,800 | 8,901,700 | 8,004,400 | 7,379,800 | 6,587,800 |
| Other shareholders' equity | 30,800 | 35,600 | -8,900 | 21,200 | 16,100 |
| TOTAL | $10,125,500 | $9,057,400 | $12,133,000 | $11,089,700 | $10,504,400 |
| Total Liabilities And Equity | $16,084,000 | $14,428,700 | $15,757,500 | $14,805,200 | $13,939,300 |